Xaira Therapeutics vs Converge Bio
Side-by-side comparison of AI visibility scores, market position, and capabilities
AI drug discovery startup launched with $1B funding. Led by ex-Stanford president + Nobel laureate David Baker. Focus: inflammatory/immunological diseases. Founded 2024, South SF.
About
Xaira Therapeutics is an AI-powered drug discovery company launched from stealth in April 2024 with $1 billion in committed capital. Headquartered in South San Francisco, incubated by Arch Venture Partners and Foresite Capital. Led by CEO Marc Tessier-Lavigne (ex-Stanford president, ex-Genentech CSO) and co-founder David Baker (Nobel laureate, UW Institute for Protein Design).
Israeli AI drug discovery company raised $25M from Bessemer; 40+ active programs; CEO co-patented CRISPR technology with Jennifer Doudna; ML platform combining target identification, hit generation, and lead optimization for oncology and immunology therapeutics.
About
Converge Bio is an Israeli AI drug discovery company using machine learning to design and optimize small molecule therapeutics across a broad portfolio of programs. Founded by a team with deep expertise in computational biology and medicinal chemistry, Converge has built a platform that combines AI-driven target identification, hit generation, and lead optimization into an integrated drug discovery engine. The company's scientific credibility is bolstered by its CEO, who co-patented CRISPR-related technology alongside Jennifer Doudna, a Nobel laureate and pioneer of gene editing.\n\nConverge operates an unusually large portfolio by biotech standards, with 40+ active drug discovery programs spanning oncology, immunology, and other therapeutic areas. The company's AI platform is designed to generate high-quality small molecule candidates faster and at lower cost than traditional medicinal chemistry approaches, enabling it to maintain a broad pipeline without the typical resource constraints of running many programs in parallel. Converge uses structure-based design, generative chemistry, and predictive ADMET modeling to advance candidates from target to preclinical candidate stage.\n\nConverge raised $25M from Bessemer Venture Partners in January 2026, bringing external validation from one of Silicon Valley's most prominent technology-focused venture firms. The funding is being used to advance lead programs toward IND filings and expand the platform's capabilities. With 40+ programs and a Nobel laureate connection in its founding story, Converge represents Israel's growing position as a global hub for AI-driven drug discovery.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.